Provide protocol development and protocol implementation relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and…
Ended Awarded Last action
- Contract number
- HHSN27200008
- Awardee
-
The University Of Iowa UEI Z1H9VJS8NG16
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $561,583
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 31% obligated
-
- $561,583.31 Current, with exercised options
- $1,812,739.31 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Iowa City, IA 52242, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$131,899 | |
| Funding Only Action | -$26,237 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $668,211 | |
| Original award | $51,508 |
About this award
This is a delivery order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $1,812,739.31 award to the University of Iowa is for protocol development and implementation related to a Phase II clinical trial evaluating the safety and efficacy of an influenza A/H7N9 vaccine. The trial will test one or two doses of the M-001 vaccine followed by one or two doses of the influenza vaccine in healthy volunteers. This work supports NIAID's Vaccine Treatment Evaluation Units (VTEU) program, which conducts clinical trials of candidate vaccines and treatments for infectious diseases. No set-aside designation was applied for this award.
Description
Provide protocol development and protocol implementation relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and immunogenicity of one or two doses of m-001 followed by one or two doses of an influenza a/H7N9 vaccine in healthy volunteers.
Quick answers
Who was awarded contract HHSN27200008?
HHSN27200008 was awarded to The University Of Iowa by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2016.
How much is contract HHSN27200008 worth?
The government has obligated $561,583 on HHSN27200008. Its potential value, with all options, is $1,812,739.
Is contract HHSN27200008 an order under another contract?
Yes. HHSN27200008 is a delivery order under HHSN272201300020I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200008 competed?
The extent of competition for HHSN27200008 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award